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reamble
he American College of Cardiology (ACC) and the
merican Heart Association (AHA) support their mem-
ers’ goal to improve the prevention and care of cardiovas-
ular diseases through professional education, research,
evelopment of guidelines and standards, and by fostering
olicy that supports optimal patient outcomes. The ACC
nd AHA recognize the importance of the use of clinical
ata standards for patient management, to assess outcomes,
nd conduct research, and the importance of defining the
rocesses and outcomes of clinical care, whether in random-
zed trials, observational studies, registries, or quality im-
rovement initiatives.
Hence, clinical data standards strive to define and stan-
ardize data relevant to clinical topics in cardiology, with
he primary goal of assisting data collection by providing a
latform of data elements and definitions applicable to
arious conditions. Broad agreement on a common vocab-
lary with reliable definitions used by all is vital to pool
nd/or compare data across studies and assess the applica-
ility of research to clinical practice. The growing adoption
f electronic medical records renders an even more imper-
tive and urgent need for such definitions and standards.
herefore, the ACC and AHA have undertaken the task of
efining and disseminating clinical data standards—sets of
tandardized data elements and corresponding definitions to
ollect data relevant to cardiovascular conditions. The ulti-
ate purpose of clinical data standards is to contribute to
he infrastructure necessary for accomplishing the ACC/
HA’s mission of fostering optimal cardiovascular care and
isease prevention.
The specific goals of clinical data standards are:
. to facilitate the establishment of registries and quality
improvement programs by providing a list of major
variables, outcomes, and definitions;
. to optimize the comparison of results and outcomes
across registries and studies; and
. to become the basis for a standardized medical docu-
mentation process, essential for the electronic medical
record environment.
The key elements and definitions are a compilation of
ariables to measure patient management and outcomes for
linical and research purposes as well as for quality improve-
ent in order to standardize the language used to describe
ardiovascular diseases and procedures, enhance consistency
n cardiology, and increase opportunities for sharing data
cross data sources. The ACC/AHA Task Force on Clin-
cal Data Standards selects cardiovascular conditions and
rocedures that will benefit from creating a data standard
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December 30, 2008/January 6, 2009:91–124 Cardiac Imaging Data Standardset. Experts in the subject are selected to examine/consider
xisting standards and develop a comprehensive, yet not
xhaustive, data standard set. When undertaking a data
ollection effort, only a subset of the elements contained in
clinical data standards listing may be needed or, con-
ersely, users may want to consider whether it may be
ecessary to collect some elements not listed. For example,
n the setting of a randomized clinical trial of a new drug,
dditional information would likely be required regarding
tudy procedures and drug therapies.
The Health Insurance Portability and Accountability Act
HIPAA) privacy regulations, which went into effect in
pril 2003, have heightened all practitioners’ awareness of
ur professional commitment to safeguard our patients’
rivacy. The HIPAA privacy regulations (http://
ww.hhs.gov/ocr/combinedregtext.pdf, page 31) specify
hich information elements are considered “protected
ealth information.” These elements may not be disclosed
o third parties (including registries and research studies)
ithout the patient’s written permission. Protected health
nformation may be included in databases used for health
are operations under a data use agreement. Research
tudies using protected health information must be reviewed
y an institutional review board or a privacy board.
We have included identifying information in all clinical
ata standards to facilitate uniform collection of these
lements when appropriate. For example, a longitudinal
linic database may contain these elements, since access is
estricted to the patient’s caregivers. On the other hand,
egistries may not contain protected health information
nless specific permission is granted by each patient. These
elds are indicated as protected health information in the
ata standards.
The ACC/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual or potential conflicts
f interest that may arise as a result of an outside relation-
hip or a personal, professional, or business interest of a
ember of the writing panel. Specifically, all members of
he writing group were required to submit a disclosure form
howing all such relationships that might be perceived as
eal or potential conflicts of interest. These statements are
eviewed by the ACC/AHA Task Force on Clinical Data
tandards, reported orally to all members of the writing
anel at the first meeting, and updated as changes occur.
riting Committee members’ relationships with industry
re listed in Appendix A. Relationships with industry for
fficial peer reviewers are listed in Appendix B.
In clinical care, caregivers communicate with each other
hrough a common vocabulary. In an analogous fashion, the
ntegrity of clinical research depends on firm adherence to
re-specified procedures for patient enrollment and follow-
p; these procedures are guaranteed through careful atten-
ion to definitions enumerated in the study design and
ase-report forms. When data elements and definitions are
tandardized across studies, comparison, pooled analysis, Cnd meta-analysis are enabled, thus deepening our under-
tanding of individual studies.
The recent development of quality performance measure-
ent initiatives, particularly those for which comparison of
roviders is an implicit or explicit aim, has further raised
wareness about the importance of data standards. Indeed, a
ide audience, including nonmedical professionals such as
ayers, regulators, and consumers, may draw conclusions
bout care and outcomes. To understand and compare care
atterns and outcomes, the data elements that characterize
hem must be clearly defined, consistently used, and prop-
rly interpreted, now more than ever before.
Véronique L. Roger, MD, MPH, FAHA, FACC
Chair, ACC/AHA Task Force on Clinical Data Standards
odality and Technique Abbreviations
sed in This Document
ACS  Coronary Artery Calcium Score
ardiac cath  Cardiac Catheterization
CT  Cardiac Computed Tomography
CTA  Cardiac Computed Tomographic
Angiography
MR  Cardiac Magnetic Resonance
cho  Echocardiography
CA  Invasive Coronary Angiography
VG  Left Ventriculography
PI  Myocardial Perfusion Imaging
ET  Positron Emission Tomography
NA  Radionuclide Angiography
PECT  Single-Photon Emission Computed
Tomography
EE  Transesophageal Echocardiography
TE  Transthoracic Echocardiography
. Introduction
ardiac imaging is an integral part of the evaluation and
anagement of patients with known or suspected heart
isease. These techniques offer insight into morphologic
eatures and physiologic functioning of the myocardium,
alves, pericardium, coronary arteries, and great vessels.
ubstantial advances in technology have occurred within the
ast decade, advancing clinical applications and enhancing
iagnostic accuracy.
Many options for imaging the heart and adjacent struc-
ures are available such as, echocardiography, single-photon
mission computed tomography (SPECT) myocardial per-
usion imaging (MPI), positron emission tomography
PET), cardiac magnetic resonance (CMR), cardiac com-
uted tomography (CCT), invasive coronary angiography
ICA), and left ventriculography (LVG). Major specialty
ocieties, such as the ACC, the AHA, the Radiological
ociety of North American (RSNA), and the American
ollege of Radiology (ACR) have demonstrated leadership
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Cardiac Imaging Data Standards December 30, 2008/January 6, 2009:91–124n promoting research and written guidelines and practice
tandards for the performance of cardiac imaging. In many
ases, each modality has developed rather independently
nd has strong advocacy by dedicated clinicians/researchers
nd their own subspecialty societies, including the American
ociety of Nuclear Cardiology (ASNC), the American
ociety of Echocardiography (ASE), the Society for Ath-
rosclerosis Imaging and Prevention (SAIP), the Society for
ardiovascular Computed Tomography (SCCT), the Soci-
ty for Cardiovascular Magnetic Resonance (SCMR), the
ociety for Cardiovascular Angiography and Interventions
SCAI), the Society of Interventional Radiology (SIR), the
orth American Society for Cardiovascular Imaging
NASCI), and the Heart Rhythm Society (HRS).
Cardiac imaging is included in patient decision-making and
s often referenced in guidelines and other data standards.
owever, differing definitions abound, leading to misunder-
tanding and confusion. Furthermore, structured reporting is
ecoming commonplace and imaging data fields are increas-
ngly being used within registries and clinical databases. The
CC has led a multisocietal effort that culminated in the
evelopment of a document that recommends the use of
tructured reporting for cardiovascular imaging as an essential
omponent of improved cardiovascular health care (1); that
rticle is being published simultaneously with these data
tandards. These two writing efforts were coordinated with
ach other and underscore the importance for capturing and
eporting clear, consistent and complete information for pa-
ients undergoing cardiovascular imaging.
The ACC/AHA Clinical Data Standards Task Force was
pproached about assembling a committee to harmonize car-
iac imaging definitions that have been developed by many
rganizations and committees, in a fashion similar to the
xisting clinical data standards for electrophysiology, ischemic
eart disease, and heart failure. The need for data standard-
zation in cardiac imaging was highlighted at a “Think Tank”
eeting sponsored by Duke University and the ACC (2). The
evelopment of common data elements was felt to be a priority
hat would lead to the development of important quality
etrics in imaging. A follow-up ad hoc group was formed as
art of a subcommittee of the ACC Cardiovascular Imaging
ollaborative Committee with a focus on quality in imaging
nd developed a working draft of data standards, which was
sed as a starting point for the Writing Committee.
I. Methodology
. Writing Committee Composition
he ACC/AHA Task Force on Clinical Data Standards
elected members for the Writing Committee to Develop
linical Data Standards for Cardiac Imaging (Writing
ommittee). The Writing Committee consisted of 15
embers who are well versed in structured reporting initi-
tives, as well as active in the various disciplines of cardiac
maging, including invasive contrast angiography, CCT, lMT, nuclear cardiology, and echocardiography. All orga-
izations listed on the masthead nominated individuals to
omprise the makeup of the Writing Committee.
. Relationships With Industry
he ACC/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual or potential conflicts
f interest that may arise as a result of an outside relation-
hip or a personal, professional, or business interest of a
ember of the writing panel. Specifically, all members of
he writing group were required to complete and submit a
isclosure form showing all such relationships that might be
erceived as real or potential conflicts of interest. These
tatements are reviewed by the ACC/AHA Task Force on
linical Data Standards and are updated when changes
ccur. Please see Appendix A for the Writing Committee
elationships with industry.
. Review of Literature and Existing Data
efinitions
hese imaging standards are intended to provide data elements
hat parallel and complement existing data fields as previously
eported in ACC and AHA documents, along with those used
s fields within existing registries, such as those developed by
he ACC National Cardiovascular Data Registry (NCDR) (3).
e also reviewed the ACC/AHA Key Data Elements and
efinitions for Measuring the Clinical Management and
utcomes of Patients with Chronic Heart Failure (4), the
CC/AHA Key Data Elements and Definitions for Measur-
ng the Clinical Management and Outcomes of Patients with
trial Fibrillation (5), the ACC/AHA/HRS 2006 Key Data
lements and Definitions for Electrophysiological Studies and
rocedures (6), and the American College of Cardiology Key
ata Elements and Definitions for Measuring the Clinical
anagement and Outcomes of Patients with Acute Coronary
yndromes (7).
. Defining Data Elements
he core elements and definitions were originally drafted by a
roup of imaging specialists formed after the first Duke/ACC
hink Tank meeting, whose proceedings were published 1
ear later (2). The Writing Committee then gathered many
ther candidate data elements gleaned from other sources. As
he Writing Committee developed definitions, they were
ncouraged to write definitions broad enough to be applicable
n a variety of data collection settings, but specific enough that
he data elements can be uniformly interpreted. Some elements
ill require an additional level of specificity by the end-user for
mplementation which is beyond the scope of the Writing
ommittee. Data definitions were linked whenever possible to
he evidence-based national guidelines. To ensure consistency
cross ACC/AHA clinical data standards, writers used an
xisting ACC/AHA definition verbatim unless there was a
eason related to cardiac imaging to change that definition.
he Writing Committee chose not to develop an all-inclusiveist of every possible data element that may be used for all
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December 30, 2008/January 6, 2009:91–124 Cardiac Imaging Data Standardsardiac imaging techniques. Rather, the Writing Committee
ocused its attention on common elements that cross modality
oundaries. It is anticipated that modality-specific data defini-
ions and elements will need further delineation, likely by
ubspecialty society organizations and groups. The purpose of
his document is to attempt to harmonize as many common
ata fields as possible. These data elements were constructed
rimarily for use with the adult cardiac patient. Therefore,
hese elements are not designed for pediatric cardiology or
hose adults with congenital heart disease.
. Prioritizing Data Elements
nce the Writing Committee reviewed the draft submitted as
working manuscript by the Think Tank Group, a focused
roup of data elements and definitions was developed. The
roup was most interested in common data elements which
ranscended an individual imaging modality. Of the data
lements included within this paper, items were identified as:
. Recommended for all imaging studies;
. Recommended for a specific modality or modalities;
. Optional, meaning a worthwhile data element but not
necessarily required in all instances;
. Derived, meaning that this field would be calculated
based on previously entered information, negating the
need to specifically obtain this information.
hese descriptors were felt to help identify the most important
ata elements for database and registry construction.
. Relation to Other Standards
he Writing Committee reviewed other standards including
hose developed for heart failure, atrial fibrillation, electrophys-
ology, and acute coronary syndromes, as previously noted.
lthough other groups have used imaging within their disci-
lines and have definitions based on imaging parameters, the
riting Committee felt that it was the responsibility of this
ultimodality group to provide a uniform standard that may
e adopted by other data standards groups for their imaging
arameters. It was felt that this Writing Committee possessed
ey levels of expertise needed to address this issue in a
onsistent fashion. It is hoped that these definitions will be
sed in subsequent revisions of the data standards for heart
ailure, atrial fibrillation, electrophysiology, and acute coronary
yndromes, in order to maintain consistency.
. Consensus Development
hese ACC/AHA data standards, like others, are team-
eveloped written documents and are based on the judg-
ents of experts within cardiovascular imaging. The Writ-
ng Committee met more than 10 times, by telephone and
n person, over the course of 5 months to define and refine
he data elements. Throughout the process, consensus was
eveloped through extensive in-person discussion, telecon-
erences, and e-mails. Minority opinions are expressed in
he discussion of the elements when differences existed. d. Peer Review, Public Review, and Board Approval
he set of imaging standards and definitions was indepen-
ently reviewed by official appointees from the ACC, AHA,
CR, ASE, ASNC, HRS, NASCI, RSNA, SAIP, SCAI,
CCT, SCMR, and SIR, as well as the ACC/AHA Data
tandards Task Force. To increase its applicability, this docu-
ent was posted on the ACC and ACR Website for a 30-day
ublic comment period from April 14, 2008, through May 14,
008. The document was then approved by all sponsoring
rganizations.
The Writing Committee anticipates these data standards
ill require review and updating, just as with guidelines,
erformance measures, and appropriateness criteria. At the
nniversary of the data standards publication, the Writing
ommittee will review the data standards to ascertain
hether or not modifications should be considered.
. Considerations for Cardiac Imaging Clinical
ata Standards
he Writing Committee anticipates that the cardiac imag-
ng data standards will prove useful in several settings:
. Clinical Programs, where providers and health plans work
in concert to achieve optimal utilization of cardiac
imaging procedures. Data standards will assist in the
development of structured reporting systems, organizing
and designing of electronic medical information systems
including clinical databasing, and decision support tools.
. Clinical Research, including prospective registries and
randomized controlled trials. Meta-analyses will be par-
ticularly strengthened by the use of standardized data for
key variables.
. Quality Assessment/Performance Measurement: data stan-
dards will especially facilitate interpretation for nonmed-
ical users, including payers, regulators, and consumers.
There is a clear need for a uniform digital standard for all
maging and clinical data (e.g., electronic health records and
ab results). These data elements for cardiac imaging are an
mportant step towards this goal.
Although this set of imaging data standards is not specifi-
ally designed to be a precursor to an imaging registry, it is clear
hat the data definitions may be used as fields for such a registry
r incorporated as data elements within registries focused on
pecific diseases, such as for heart failure or ischemic heart
isease. Additionally, it is hoped that these standards will be
sed for definition within the information technology commu-
ity to standardize textual cardiac imaging data and to be
ncorporated within structured reporting programs. An ongo-
ng dialogue with key groups, including Digital Imaging and
ommunications in Medicine (DICOM) and Integrating the
ealthcare Enterprise (IHE), will ensure data harmonization
nd uniformity.
The Writing Committee discussed the overall philosophy of
hese standards at great length, including whether or not to
evelop comprehensive or focused data elements. As multiple
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Cardiac Imaging Data Standards December 30, 2008/January 6, 2009:91–124odalities were included within this standard, it was decided
o include key elements only and those in which there was
verlap among modalities.
It is anticipated that these standards will not be compre-
ensive enough for all needs, and additional elements may
eed to be created for modality-specific findings. This
ultimodality data standards document, however, aims to
efine elements which cross modality barriers. The empha-
is for this effort was on harmonization among the imaging
odalities whenever possible, such as when defining isch-
mia or ventricular function.
A modular approach to the use of these imaging data
tandards should be considered. Certain data definitions are
pplicable only to an indication, such as detection of ischemia.
s such, only the imaging methods of stress echocardiography,
tress SPECT MPI, and stress CMR would need to define the
resence, absence, and extent of ischemia. Likewise if no
ntracardiac shunting were detected, then completion of fields
efining the presence of a patent foramen ovale or ventricular
eptal defect would not be required.
Whenever feasible, the Writing Committee attempted to
ncorporate existing definitions into this document. For exam-
le, data elements involving identification of the patient or
hysician have already been published and replicated within
his document. Likewise, defining hypertension or heart failure
ave been previously described and are beyond the scope of this
aper. However, other publications have already included
efinitions of image-related data which the Writing Commit-
ee felt were either inaccurate or not optimally described, and it
s the hope of this group that the standards defined in the
urrent document will be used in future, revised versions of
ther guidelines and data standards.
Two categories of data elements deserve special mention.
he Writing Committee firmly supports standardization of
omenclature for left ventricular (LV) segmentation, which
as initially supported by all imaging modalities (8) but noties with use of regions or territories that are defined within a
pecific modality, the 17-segment model was felt to reflect a
easonable, previously published standard, which should be
upported. The size of the abnormality can then be defined by
he number of segments affected. A second area of intense
iscussion involved defining LV function and ejection fraction
etermination. Once again the Writing Committee empha-
ized the unique opportunity to help clarify LV function,
hich has many definitions depending on the imaging modal-
ty and method of analysis. The composition of this group
epresenting all key organizations associated with cardiac im-
ging permitted a unique opportunity for resolving this “tower
f Babel.”
II. Cardiac Imaging Clinical Data Standard
lements and Definitions
. Administrative
here are a total of 6 administrative elements: site ID, site of
ervice, cardiac imaging service, accreditation status, accredita-
ion entity, and insurance payer. Ideally, the information from
hese elements could be provided to the registry once, at the
ime of site registration, and associated with the site ID, thus
ecreasing the number of elements requiring data entry at the
ime of recruitment. Recruitment sites would include a wide
ariety of facilities: private practice settings, academic centers,
oth in-patient and outpatient facilities, and emergency de-
artments. As such, a specific institution might have several
ite IDs, one for each provided service, as patients may be
ntered into the registry from different departments providing
he different services described.
The insurance payer element was included to be certain
hat patients of all payer status were included in studies
quitably, especially those funded federally. The inclusion of
his data was not to in any way suggest that cardiac imagingniversally adopted. Rather than describe imaging abnormali- patients should be screened on the basis of ability to pay.
able 1. Administrative
Element Name Definition
ite ID (Recommended) Site ID is a unique number assigned to each database site. A database site is defined as 1 entity that signs a site agreement,
submits 1 data submission file to the harvest, and gets back 1 report on their data.
Each site’s data if submitted to be analyzed must be in 1 data submission file. If 1 site keeps their data in more than 1 file
(e.g., at 2 sites), then the data must be combined into a single data submission file for the harvest.
If 2 or more sites share a single purchased software, and enter cases into 1 database, then the data must be exported into different
data submission files, 1 for each Site ID.
ite of service
(Optional)
Indicate the type of facility submitting the reporting data.
Choose 1 of the following:
● Hospital—inpatient
● Hospital—outpatient
● Nonhospital—inpatient
● Nonhospital—outpatient
● Mobile-based—inpatient
● Mobile-based—outpatient
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he HIPAA privacy regulations specify which elements are
onsidered “protected health information (PHI).” These
lements may not be disclosed to third parties (including
able 1. Continued
Element Name
ardiac imaging
services
(Recommended)
Indicate the cardiac imaging services provided by th
Choose any of the following:
● Echocardiography
● CCT
● CMR
● SPECT MPI
● PET
● ICA/LVG
maging facility:
address
(Recommended)
Indicate the physical location of the facility which m
country.
maging facility:
telephone
(Recommended)
Indicate the number that uniquely identifies a teleco
ource(s) of information
(Recommended)
May select more than 1:
● Patient
● Referring clinician
● Laboratory
● Medical record
● Other
riority of study
(Recommended)
Designate the study as 1 of the following:
● Routine
● STAT
ccreditation status
(Recommended)
For each imaging service provided by the site, indica
Choose 1 of the following for each imaging service:
● Yes
● Application submitted, pending approval
● No
ccreditation entity
(Recommended)
If the site is accredited, indicate the entity providing
Choose any of the following:
● American College of Radiology
● ICAEL
● ICANL
● ICACTL
● ICAMRL
● Other
● N/A
nsurance payer
(Recommended)
Indicate the appropriate description of the patient’s
all that apply:
● Medicare—A federal health care plan that reimbu
age 65 years or older, people under age 65 years
● Medicaid—Any state and federal health care progr
who cannot finance their own medical expenses.
● Commercial—Any health insurance provided by a
This includes managed care plans, such as HMOs
● Military/VAMC—Refers to any military or Veteran’s
● Non-U.S. Insurance—Refers to individuals with no
to pay.
● Self/None—Refers to situations when the individu
“self” or “none” is listed as the first insurance in t
/A indicates not applicable.egistries and research studies) without the patient’s written uermission. PHI may be included in databases used for
ealth care operations under a data use agreement. Research
tudies using PHI must be reviewed by an institutional
eview board or a privacy board. PHI will then need to be
Definition
.
described using street address, city, state or province, postal code, and
nications connection of the facility.
accreditation status of the site performing the study.
ccreditation for each imaging modality.
nce carrier(s) for this admission. If the patient has more than 1, choose
ospitals and physicians for medical care provided to qualifying people
certain disabilities, and people of all ages with end-stage renal disease.
at reimburses hospitals and physicians for providing care to qualifying people
ercial plan, regardless of the type of restrictions or payment arrangements.
s, POSs, and IPAs.
inistration Health Plans, and PHS.
ited health insurance; thus, the individual is the payer regardless of ability
e sole payer regardless of his/her ability to pay. Check this choice only when
dical record.e site
ay be
mmu
te the
the a
insura
rses h
with
am th
comm
, PPO
Adm
or lim
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he mencoupled from any identifying information. One possible
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dentifier (i.e., 1-way hash number) (9,10) computer gener-
ted by immutable patient statistics. Cross-linkage of data
egarding various imaging procedures is essential for evalu-
tion of possibly redundant and serial testing, but the means
o accomplish this task are beyond the scope of this project
nd the charge of the Writing Committee.
. Study Referral Data
t is important to capture the referral source data for
urposes of studying trends in referral patterns over time
nd to determine the utilization of cardiac imaging. The use
f the National Physician Identifier (NPI) was chosen to
niquely and longitudinally track referral physician, partic-
larly in longstanding studies and in the case of physicians
hat change geographic or institutional venues. The Referral
hysician Specialty element was designed to capture the
ost likely specialty groups to be referring patients for
ardiac imaging studies; the level of granularity for this
lement was discussed at length, and the final decision was
o include a representative list, rather than a comprehensive
able 2. Demographics
Element Name Definition
nique patient ID
(Recommended)
Participant ID is a unique number that permanently
identifies each patient. Once assigned to a
patient, this can never be changed or reassigned
to a different patient. If a patient returns to the
site, they MUST receive this same unique patient
identifier.
atient DOB
(Recommended)
Indicate the patient’s date of birth
ender
(Recommended)
Indicate the patient’s gender at birth as either male
or female.
Choose 1 of the following:
● Male
● Female
ace
(Recommended)
Indicate the patient’s race as determined by the
patient/family.
Choose 1 of the following:
● Caucasian
● Black
● Asian
● Native American or Alaska Native
● Native Hawaiian or other Pacific Islander
● Other race not listed
thnicity
(Recommended)
Indicate if the patient is of Hispanic ethnicity as
determined by the patient/family. Hispanic
ethnicity includes patient reports of Cuban,
Mexican, Puerto Rican, South or Central
American, or other Spanish culture or origin,
regardless of race.
Choose 1 of the following:
● Yes
● Noll-inclusive list of likely physician referrers. i. History and Risk Factors
nformation about a patient’s medical history and risk
actors obtained prior to an imaging test is important
or quality performance measurement, clinical research,
nd clinical care. Presence of cardiac risk factors or
ymptoms may impact interpretation of findings and are
ecessary to track the appropriate use of imaging tests.
edical history may impact the imaging test chosen or
lter the technical approach of an imaging test in an
ffort to maximize diagnostic yield. Medical history is
lso critical to ensure the safety of an imaging test, as it
ay reveal absolute or relative contraindications to an
maging modality or agents used in performance of an
maging test.
The medical history and risk factors data elements
hosen for inclusion in this document are intended to
eproduce standard elements in other data standard
ocuments and to adhere to current consensus guidelines
n the classification of disease states whenever possible.
n addition, elements were constructed with the spe-
ific purpose of tracking applications of relevant Appro-
riateness Criteria and Consensus Practice Guidelines in
hich imaging tests are prominent (e.g., Perioperative
uidelines for Noncardiac Surgery [11]). Some of the
lements in this area may be derived from others using
tandard risk-factor calculation tools. The Writing
roup recognizes that all historical information included
ay not be routinely available for all imaging tests
nd that more detailed information may be necessary/
outine prior to specific imaging tests or for specific
able 3. Study Referral Data
Element Name Definition
hysician NPI—Referral
physician
(Recommended)
Indicate the participant’s National Provider
Identifier (NPI). This number, assigned
by the Centers for Medicare & Medicaid
Services (CMS), is used to uniquely
identify physicians for Medicare billing
purposes.
eferral physician specialty
(Recommended)
Indicate the primary specialty of the
physician referring the patient.
● Cardiologist
● Family practice
● Internal medicine
● OB/GYN
● Hospitalist
● Surgeon
● Physician extender
● Anesthesiologist
● Radiologist
● Emergency department physician
● Otherndications.
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Element Name Definition
eight (cm)
(Recommended)
Indicate the patient’s first recorded height in centimeters at the time of the study. If not in cm, list units. To be converted
from English units if needed.
eight (kg)
(Recommended)
Indicate the patient’s first recorded weight in kilograms at the time of the study. If not in kg, list units. To be converted
from English units if needed.
stimated ability to exercise
(prior to test), described in METS
(Recommended—stress SPECT,
stress TTE, stress CMR, stress
PET)
Indicate the ability of the patient to meet estimated energy requirements for various activities expressed as a number of
metabolic equivalents.
Choose 1 of the following:
● Less than 4 METS—defined as ability to do 1 or more of the following activities (can take care of oneself, eat, dress, or
use the toilet, walk indoors around the house, or walk a block or 2 on level ground at 2 to 3 mph or 3.2 to 4.8 km/h)
● 4 METS or greater—defined as the ability to do 1 or more of the following activities (climb a flight of stairs or walk
uphill, walk on level ground at 4 mph or 6.4 km/h, run a short distance, do heavy work around the house such as
scrubbing floors or lifting or moving heavy furniture, participate in moderate recreational activities like golf, bowling,
dancing, doubles tennis, or throwing a baseball or football, or participate in strenuous sports like swimming, singles
tennis, football, basketball or skiing)
ypertension
(Recommended)
Indicate if the patient has a current diagnosis of hypertension defined by any 1 of the following:
● History of hypertension diagnosed and treated with medication, diet, and/or exercise
● Prior documentation of blood pressure greater than 140 mm Hg systolic and/or 90 mm Hg diastolic for patients
without diabetes or chronic kidney disease, or prior documentation of blood pressure greater than 130 mm Hg systolic
or 80 mm Hg diastolic on at least 2 occasions for patients with diabetes or chronic kidney disease
● Currently on pharmacological therapy for the treatment of hypertension.
Choose 1 of the following:
● Yes
● No
● Unknown
ystolic blood pressure
(Recommended)
Indicate most recent systolic blood pressure (mm Hg) reading during visit for the imaging study.
iastolic blood pressure
(Recommended)
Indicate most recent diastolic blood pressure (mm Hg) reading during visit for the imaging study.
yslipidemia
(Recommended)
Indicate if the patient has a history of dyslipidemia diagnosed and/or treated by a physician. National Cholesterol
Education Program (12) criteria include documentation of the following:
● Total cholesterol greater than 200 mg/dl (5.18 mmol/l)
● Low-density lipoprotein (LDL) greater than or equal to 130 mg/dl (3.37 mmol/l)
● High-density lipoprotein (HDL) less than 40 mg/dl (1.04 mmol/l) in men and less than 50 mg/dl (1.30 mmol/l)
in women
● Currently on antilipidemic treatment
Choose 1 of the following:
● Yes
● No
● Unknown
DL
(Optional)
Indicate most recent LDL measurement (mg/dl) in medical record prior to imaging study.
DL
(Optional)
Indicate most recent HDL measurement (mg/dl) in medical record prior to imaging study.
amily history of coronary
artery disease
(Recommended)
Any first-degree relatives (parents, siblings, children) who have had any of the following at age less than 55 years:
1. Angina, 2. Myocardial infarction (MI), 3. Coronary artery bypass graft (CABG), 4. Percutaneous coronary intervention
(PCI), or 5. Sudden cardiac death without obvious cause.
Choose 1 of the following:
● Yes
● No
● Unknown
istory of tobacco use
(Recommended)
Indicate if the patient has a history confirming any form of tobacco use in the past. This includes cigarettes, cigar,
tobacco chew, etc.
Choose 1 of the following:
● Yes, Current: Use of tobacco within 1 month of this study.
● Yes, Former: Use of tobacco greater than 3 months prior to this study.
● Never
● Unknown
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Element Name Definition
iabetes
(Recommended)
Indicate if the patient has a history of diabetes mellitus, regardless of duration of disease or need for antidiabetic
agents; or a fasting blood sugar greater than 7 mmol/l or 126 mg/dl. This includes diagnosis at any time prior to the
study. It does not include gestational diabetes.
Choose 1 of the following:
● Yes—insulin requiring
● Yes—noninsulin requiring
● No
● Unknown
istory of acute renal failure
(Recommended)
Indicate if the patient has a history of acute renal failure, which is defined as history of reduced renal function (GFR
greater than 30) for less than 3 months.
Year of occurrence and precipitant for acute renal insufficiency may be specified.
istory of chronic kidney disease
(Recommended)
Indicate if the patient has a history of chronic kidney disease, which is defined as either kidney damage or GFR less than
60 ml/min/1.73 m2 for greater than or equal to 3 months. Kidney damage is defined as pathologic abnormalities or
markers of damage, including abnormalities in blood or urine tests or imaging studies.
Indicate the patient’s stage of disease (13):
● Stage 0—No known kidney disease
● Stage 1—Kidney damage with normal or high—GFR greater than or equal to 90 ml/min/1.73 m2
● Stage 2—Kidney damage with mildly decreased—GFR 60 to 89 ml/min/1.73 m2
● Stage 3—Moderately decreased—GFR 30 to 59 ml/min/1.73 m2
● Stage 4—Severely decreased—GFR 15 to 29 ml/min/1.73 m2
● Stage 5—Kidney failure—GFR less than 15 ml/min/1.73 m2 or on dialysis
● Unknown
eripheral arterial disease
(Recommended)
Indicate if the patient has a history of peripheral arterial disease (includes upper and lower extremity, renal, mesenteric,
and abdominal aortic systems).
This can include:
● Claudication, either with exertion or at rest
● Amputation for arterial vascular insufficiency
● Vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities (excluding dialysis fistulas and
vein stripping)
● Documented aortic aneurysm with or without repair
● Positive invasive angiogram
● Positive noninvasive test (e.g., ankle brachial index less than or equal to 0.9, ultrasound, magnetic resonance or
computed tomography imaging of greater than 50% diameter stenosis in any peripheral artery, i.e., renal, subclavian,
femoral, iliac).
Choose 1 of the following:
● Yes
● No
● Unknown
erebrovascular disease
(Recommended)
Indicate if the patient has a history of cerebrovascular disease, including any 1 of the following:
● Cerebrovascular accident (CVA): Patient has a history of stroke, i.e., loss of neurological function with residual
symptoms at least 24 h after onset, presumed to be from vascular etiology.
● Transient ischemic attack (TIA): Patient has a history of loss of neurological function that was abrupt in onset but with
complete return of function within 24 h, presumed to be due to vascular etiology.
● Noninvasive/invasive carotid test with greater than greater than or equal to 80% occlusion.
● Previous carotid artery surgery/intervention for carotid artery stenosis.
This does not include neurological disease processes such as metabolic and/or anoxic ischemic encephalopathy.
Choose 1 of the following:
● Yes
● No
● Unknown
rectile dysfunction
(Optional)
Indicate if the patient has a history of erectile dysfunction.
Choose 1 of the following:
● Yes
● No
● Unknown
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Element Name Definition
stimated cardiac event risk
(Recommended—stress SPECT,
stress PET, stress TTE, CCTA,
CACS, stress CMR)
Indicate the coronary (Framingham) risk (calculated based on published criteria at the NHLBI Web site [14]) of
myocardial infarction or cardiac death based on clinical history of the patient as estimated at the study site.
Choose 1 of the following:
● Low (less than 10% 10-year risk)
● Intermediate (10% to 20% 10-year risk)
● High (greater than 20% 10-year risk or a coronary risk equivalent as defined by ATPII/NCEP (diabetes, PAD, etc.)
● N/A
alculated cardiac event risk
(Derived)
Indicate the patient’s calculated cardiac (Framingham) risk (calculated based on published criteria at the NHLBI Web
site [14]):
● Low (less than 10% 10-year risk)
● Intermediate (10% to 20% 10-year risk)
● High (greater than 20% 10-year risk or a coronary risk equivalent as defined by ATPII/NCEP (diabetes, PAD, etc.)
● N/A
istory of arrhythmias
(Recommended)
Indicate whether the patient has a history of the following arrhythmias.
Choose any of the following:
● Frequent PVCs
● Sinus tachycardia
● Ventricular tachycardia
● Atrial fibrillation
● Atrial flutter
● Other
● None
istory of asthma or
bronchospasm
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
Indicate if the patient has a history of asthma or bronchospasm:
● Yes
● No
● Unknown
revious pacemaker or
implantable cardioverter-
defibrillator (ICD) insertion
(Recommended)
Pacemaker or ICD implantation prior to the current encounter. Device type (pacemaker, ICD, combination), cardiac
chamber(s) involved, and year of implantation may be helpful.
Choose 1 of the following:
● Yes
● No
istory of heart failure
(Recommended)
History of heart failure, per medical record, physician, or patient history
● Yes
● No
ew York Heart Association
(NYHA) functional class
(Optional)
If heart failure, indicate NYHA functional class (15)
Choose 1 of the following:
● Class I: patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity
does not cause undue fatigue, palpitation, or dyspnea.
● Class II: patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Ordinary physical activity results in fatigue, palpitation, or dyspnea.
● Class III: patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Less than ordinary activity causes fatigue, palpitation, or dyspnea.
● Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Symptoms are present even at rest or minimal exertion).
anadian Cardiovascular
Angina Class
(Optional)
If angina, indicate the Canadian Cardiovascular Angina class.
Choose 1 of the following:
● 0. Asymptomatic. No angina.
● 1. Ordinary physical activity (e.g., walking or climbing stairs) does not cause angina; angina occurs with strenuous or
rapid or prolonged exertion at work or recreation
● 2. Slight limitation of ordinary activity (e.g., angina occurs walking or stair climbing after meals, in cold, in wind, under
emotional stress, or only during the few hours after awakening; walking more than 2 blocks on the level or climbing
more than 1 flight of ordinary stairs at a normal pace; and in normal conditions)
● 3. Marked limitation of ordinary activity (e.g., angina occurs with walking 1 or 2 blocks on the level or climbing 1 flight
of stairs in normal conditions and at a normal pace)
● 4. Inability to perform any physical activity without discomfort; angina syndrome may be present at rest
● 5. N/A
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Element Name Definition
hest pain symptoms or suspected
angina equivalent
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
Indicate whether chest pain or discomfort, dyspnea/shortness of breath suspected to be anginal equivalent, or other
suspected anginal equivalent has been documented within the past month.
Choose 1 of the following:
● Yes
● No
● Unknown
tability of chest pain symptoms
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
Indicate the patient’s angina type:
● Atypical chest pain
● Stable angina
● Unstable angina
● Myocardial infarction
haracteristics of chest
pain/discomfort or suspected
angina equivalent
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
If chest pain or discomfort has been documented, indicate all characteristics of the chest pain or discomfort.
Choose 1 or more of the following:
● Substernal chest pain or discomfort
● Provoked by exertion or emotional distress
● Relieved by rest and/or nitroglycerin
ngina type
(Derived from previous element)
Indicate the angina type based on the characteristics of chest pain/discomfort or suspected angina equivalent.
● Typical angina (definite)—the chest pain or discomfort has all three characteristics recorded in the previous element.
● Atypical angina (probable)—the chest pain or discomfort recorded in the previous element lacks one of the three
characteristics.
● Nonanginal chest pain—the chest pain or discomfort recorded in the previous element meets one or none of the typical
angina characteristics.
● N/A due to absence of chest pain
re-test probability of coronary
artery disease
(Derived)
If chest pain or discomfort has been documented, calculate the pre-test probability of obstructive CAD. Choose 1 of the
following:
● Low (less than 10%)
● Intermediate (10% to 90%)
● High (greater than 90%)
● Known CAD
● N/A, no chest pain or anginal equivalent
CG interpretable for ischemia
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
Indicate whether the ECG is interpretable for ischemia if used as part of a stress test.
Choose 1 of the following:
● Yes
● No [resting ST-segment depression (greater than or equal to .10 mV), complete left bundle-branch block (LBBB),
pre-excitation (Wolf-Parkinson-White Syndrome), left ventricular hypertrophy, digoxin use, or paced rhythm]
● Equivocal
● N/A
revious diagnostic test
and date
(Recommended)
Indicate diagnostic imaging test within the last 24 months.
Select all applicable from the following:
● Stress SPECT MPI
● Stress TTE
● TTE
● TEE
● CACS
● CCTA
● CMR
● Invasive coronary angiography
● ECG—only stress test
● Unknown
● None
Include the date of the test. If the month and day are unknown, the year is sufficient.
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Element Name Definition
revious diagnostic imaging
test result
(Optional)
Indicate documented and verified findings of previous diagnostic imaging study.
Select all that apply:
● Coronary artery stenosis greater than or equal to 50%
● Coronary artery stenosis less than 50% stenosis
● Myocardial ischemia
● Scar/MI
● Cardiac mass/thrombus/vegetation
● Significant LV systolic dysfunction
● Pericardial disease
● Valvular heart disease
● Congenital heart disease
● Nondiagnostic
● Not applicable
revious MI
(Recommended)
History of MI by patient history, medical records, or physician
Choose 1 of the following:
● Yes
● No
ate of previous MI
(Optional)
If the patient had a previous MI, indicate the date of most recent MI. If the month and day are unknown, the year is
sufficient.
revious PCI
(Recommended)
Indicate if the patient had a previous percutaneous intervention (PCI) (even if unsuccessful) of any type (balloon
angioplasty, stent or other), performed prior to the study.
Choose 1 of the following:
● Yes
● No
revious PCI—date
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
If the patient had a previous PCI of any type (balloon angioplasty, stent or other), performed prior to the current study,
indicate the date of the most recent PCI. If the month and day are unknown, the year is sufficient.
revious CABG
(Recommended)
Indicate if the patient had a previous coronary artery bypass graft surgery (CABG) by any approach.
Choose 1 of the following:
● Yes
● No
revious CABG—date
(Recommended—stress TTE,
stress SPECT, stress PET, CCTA,
stress CMR)
If the patient had a previous CABG prior to the current admission, indicate the date of the most recent CABG. If the
month and day are unknown, the year is sufficient.
oncardiac surgery—risk
of procedure
(Recommended if
pre-operative)
If the patient is scheduled for surgery, indicate the cardiac risk (incidence of cardiac death and nonfatal myocardial
infarction) from the surgery itself.
Choose 1 of the following:
● Low-risk surgery (less than 1%; e.g., endoscopic procedures, superficial procedures, cataract surgery, breast surgery)
● Intermediate-risk surgery (less than 5%; e.g. intraperitoneal and intrathoracic surgery, carotid endarterectomy, head
and neck surgery, orthopedic surgery, prostate surgery)
● High-risk surgery (greater than or equal to 5%, e.g., emergent major operations, aortic or other major vascular surgery,
peripheral vascular surgery, anticipated prolonged surgical procedure associated with large fluid shifts and/or blood
loss)
● N/A
oncardiac surgery—patient
active conditions
(Recommended if
pre-operative)
For a patient scheduled to undergo noncardiac surgery, does the patient have any active cardiac conditions; defined as
any of the following:
● Unstable coronary syndrome
● Decompensated heart failure (NYHA functional class IV, worsening or new heart failure)
● Significant arrhythmias (e.g., high-grade AV block, ventricular arrhythmias, symptomatic bradycardia, supraventricular
arrhythmias with an uncontrolled rate)
● Severe valvular heart disease
Choose 1 of the following:
● Yes
● No
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Element Name Definition
oncardiac surgery—patient
risk factors
(Recommended if
pre-operative)
For a patient scheduled to undergo noncardiac surgery, how many of the following clinical risk factors are present:
● Ischemic heart disease
● Compensated or prior heart failure
● Diabetes mellitus
● Renal insufficiency
● Cerebrovascular disease
Choose 1 of the following:
● 3 or more
● 1 to 2
● None
edication ID—medications
(Recommended)
(Optional—TEE, TTE)
Indicate which of the following categories of medications are routinely taken by the patient. Choose all applicable of the
following:
● ACE inhibitor/angiotensin receptor blocker
● Aspirin, other antiplatelet agents
● Calcium channel blockers
● Beta-blockers
● Erectile dysfunction medication
● Nitrates
● Warfarin
● Antiarrhythmics
● Digitalis
● Metformin
● Lipid-lowering medication (niacin, statins, fibrates, etc.)
● Other antihypertensives
● Aminophylline or theophylline
● Dipyridamole
● Inhaler
● Diabetic medications
● None
edications—normally used but
held prior to testing
(Recommended)
(Optional—TEE, TTE)
Indicate if any medications normally used by the patient that were not administered per routine schedule prior to test:
● ACE inhibitor/angiotensin receptor blocker
● Aspirin, other antiplatelet agents
● Calcium-channel blockers
● Beta-blockers
● Erectile dysfunction medication
● Nitrates
● Warfarin
● Antiarrhythmics
● Digitalis
● Metformin
● Lipid-lowering medication (niacin, statins, fibrates, etc.)
● Other antihypertensives
● Aminophylline or theophylline
● Dipyrdiamole
● Inhaler
● Diabetic medications
● None
istory of reaction to
contrast agent
(Recommended)
If history of reaction to contrast agent, list all applicable:
● Iodinated
● Gadolinium
● Echocardiography agent
● Radionuclide
● N/A/A indicates not applicable.
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he study description includes a categorical designation of
he imaging modality employed. The specific physician
nvolved in the interpretation of the study should be noted,
long with his/her credentials. Subsequent elements further
escribe the details of the method used to perform the
able 5. Study Description
Element Name
tudy ID
(Recommended)
Unique study identifier.
tudy acquisition date
(Recommended)
Indicate the date of the image acquisition.
hysician NPI—study
interpretation and report
(Recommended)
Indicate the National Provider Identifier (NPI) of
by the Centers for Medicare & Medicaid Servic
there is more than one physician, enter the bi
hysician board
certification—study
interpretation and report
(Recommended)
Indicate the Board certification of the physician
Choose 1 or more of the following:
● Cardiovascular Disease
● Internal Medicine
● Radiology
● Nuclear Medicine
● Other
● None
hysician subspecialty
certification—study
interpretation and report
(Recommended)
Indicate whether the physician interpreting the s
imaging modality being performed.
● Certification Board of Nuclear Cardiology (CBNC
● American Board of Nuclear Medicine (ABNM)
● Certification Board of Cardiovascular Computed
● National Board of Echocardiography, Inc. (NBE)
● Certificate of Added Qualification—Nuclear Me
● American Board of Internal Medicine Certificat
● American Board of Internal Medicine Certificat
● Certificate of Proficiency in CCTA (ACR)
maging study performed
(Recommended)
Indicate the type of diagnostic imaging test perf
Choose 1 of the following:
● Nuclear: SPECT MPI
● Nuclear: PET
● Nuclear: RNA
● Echocardiography: stress TTE
● Echocardiography: TTE
● Echocardiography: TEE
● CCT: CACS
● CCT: CCTA
● CCT: CACS and CCTAxamination. This generally includes technical elements of
mage acquisition specific to the modality, use of an imaging
gent, i.e., contrast or radionuclide, and, if stress testing was
erformed, the method of stress testing. The primary and
econdary indications for the study are also included in this
ection.
Definition
ysician interpreting the study and producing the report. This number, assigned
MS), is used to uniquely identify physicians for Medicare billing purposes. If
hysician’s NPI.
reting the study and producing the report.
nd producing the report holds a subspecialty certification specific to the
ography (CBCCT)
(ACR)
Interventional Cardiology
Electrophysiology
.● CMR: CMR
● CMR: stress CMR
● Cardiac catheterization: ICA
● Cardiac catheterization: ICA and LVG
cquisition parameters:
Contrast/imaging
agent use
(Recommended)
If echo, CCT, or CMR study was performed, indicate whether contrast or radiopharmaceutical was used during the study.
Choose 1 of the following:
● Yes
● Nothe ph
es (C
lling p
interp
tudy a
)
Tom
dicine
ion in
ion in
ormed
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Element Name Definition
cquisition parameters:
Echocardiography
(Recommended—
TTE/TEE)
If TTE or TEE was performed, indicate the acquisition parameter used. Choose all applicable from the following:
● M-mode and 2-D
● 3-D
● Spectral Doppler
● Doppler—color
● Perfusion
● Tissue Doppler
● Other
cquisition parameters:
Contrast use
(Recommended)
List all contrast/imaging agents used:
● Radionuclide
—F-18 FDG for viability
—Rubidium-82 perfusion
—Nitrogen-13 ammonia perfusion
—Tc-99m tetrofosmin (Myoview)
—Tc-99m sestamibi (Cardiolite)
—Tl-201
● Echo contrast
—Optison (Perflutren)
—Definity (Perflutren Lipid Microsphere)
—Agitated saline
—Iodinated contrast
● High osmolar contrast media (ionic)
—Diatrizoate meglumine and diatrizoate sodium (Renografin, etc.)
—Ioxithalamate (Telebrix)
—Iothalamate dimeglumine (Conray)
● Low osmolar nonionic contrast media
—Iopamidol (Isovue)
—Iohexol (Omnipaque)
—Ioversol (Optiray)
—Ioxaglate (Hexabrix)
—Iomeprol (Iomeron)
—Iopromide (Ultravist)
● Iso-osmolar nonionic contrast media
—Iodixanol (VisiPaque)
● Paramagnetic agent
—Gadopentetate dimeglumine (Magnevist)
—Gadodiamide (Omniscan)
—Gadoversetamide (Optimark)
—Gadobenate dimeglumine (MultiHance)
● None
cquisition parameters for
SPECT or PET:
Radionuclide dose
(Recommended)
If radionuclide was used during the study, indicate the dose of each radiopharmaceutical in mCi.
cquisition parameters:
Gating
(Recommended—CCT,
CMR, SPECT, PET)
If a nuclear, CCT, or CMR study was performed, indicate whether gating was used.
Choose 1 of the following:
● Yes
—Prospective
—Retrospective
—Both
● No
cquisition parameters:
Attenuation correction
(Recommended—SPECT,
PET)
If a SPECT/PET study was performed, indicate whether attenuation correction was used for the nuclear imaging study.
Choose 1 of the following:
● Yes
● No
TA
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Element Name Definition
cquisition parameters for
CCT: Number of slices
(Recommended)
If CCT was the study performed, indicate if the number of “slices” was greater than or equal to 64.
Choose 1 of the following:
● Yes
● No
cquisition parameters for
CCT: Temporal resolution
(Optional)
If CCT was the study performed, indicate the gantry rotation speed in milliseconds.
cquisition parameters for
CCT: Contrast volume
(Recommended)
If iodinated or paramagnetic contrast was used during the study, indicate the volume of contrast used, in milliliters (ml) or not used.
cquisition parameters for
CCT: Radiation exposure
(Recommended)
If a CCT was performed, indicate the total radiation exposure in mGy cm (the dose-length product).
cquisition parameters:
Medications used
(Recommended)
Indicate whether or not a medication was used during the procedure.
Choose 1 or more of the following:
● Beta-blocker
● Nitrates
● Calcium-channel blocker
● Aminophylline
● None
cquisition parameters:
Heart rate (bpm) during
acquisition
(Recommended—CTA)
Indicate the heart rate (bpm) during acquisition.
cquisition parameters for
CMR: Method
(Recommended—CMR)
If CMR was the study performed, indicate the methods used.
Choose 1 or more of the following:
● Morphology and function
● Delayed enhancement
● Flow/velocity quantification
● MR angiography
● Perfusion
● Other
cquisition parameters for
catheterization:
Fluoroscopy time
(Recommended)
Indicate total fluoroscopy time recorded, during the catheterization laboratory visit, to the nearest 0.1 min. The time recorded should
include the total time for the procedure.
rimary clinical reason
for test
(Recommended)
Choose 1 of the following:
● Detection of CAD
● Risk assessment of CAD
● Pre-operative assessment
● Post-revascularization assessment
● Determination of viability—candidacy for revascularization
● Congenital heart disease
● Pericardial disease
● Pulmonary vein assessment
● Cardiac morphology (including cardiac mass)
● Assessment of ventricular function
● Evaluation for cardiomyopathy
● Evaluation for valvular heart disease
● Evaluation for great vessels
● Symptom/signs evaluation not related to above categories
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ommonly recognized confounding factors in the baseline
lectrocardiographic recording, including Q waves, abnor-
al rhythm, ST-segment depression, and evidence of ven-
ricular pacing or conduction abnormalities, should be noted
ue to their potential negative impact on the interpretability
f the ECG recording during any subsequent stress testing
or inducible ischemia.
For any exercise stress testing performed, the number of
etabolic equivalent tasks (a.k.a. METS) may be noted to
eflect exercise capacity. A recording of the nature of any
nduced chest pain, along with the maximum amount of
able 5. Continued
Element Name
ther clinical reasons
for test
(Optional)
Choose any of the following:
● Detection of CAD
● Risk assessment of CAD
● Pre-operative assessment
● Post-revascularization assessment
● Determination of viability
● Congenital heart disease
● Pericardial disease
● Pulmonary vein assessment
● Cardiac morphology (including cardiac mass)
● Assessment of ventricular function
● Evaluation of cardiomyopathy
● Evaluation of valvular heart disease
● Evaluation of great vessels
● Assessment of symptoms suspected of cardiac
● No other indication
ype of stress
(Recommended—stress
CMR, stress TTE, stress
SPECT, stress PET)
Indicate if both pharmacologic stress testing and
Choose 1 of the following:
● Exercise
● Pharmacologic
● Combined exercise and pharmacologic
ype of stress: Exercise
(Recommended)
If exercise stress testing was performed during t
Choose 1 of the following:
● Bicycle
● Treadmill exercise testing
—Naughton
—Bruce
—Modified Bruce
—Low level
—Other
ype of stress:
Exercise time
(Recommended)
If exercise stress testing was performed during t
ype of stress:
Pharmacologic
(Recommended)
If pharmacologic stress testing was performed d
● Adenosine
● Atropine
● Dipyridamole
● Dobutamine
● Regadenoson
● Other
/A indicates not applicable.T-segment depression, should be recorded. sChanges in both heart rate (HR) and in blood pressure
BP) components, from baseline to maximum, should be
oted to reflect the physiologic response to any stress testing
erformed. Achievement of at least 85% of maximum
redicted HR is to be used to assess adequacy of the stress,
nd together, achieved HR and achieved BP, permit calcu-
ation of the double product. HR recovery from peak
xercise may be used to further assess physiologic response
o stress.
Regardless of the measure of myocardial ischemia in-
uced by stress testing (evoked hypoperfusion or ventricular
ysfunction) and/or the measure of post-infarct myocardial
Definition
gy
cise stress testing were performed.
dy, indicate the type of protocol used to perform the study.
dy, indicate exercise duration in minutes.
the study, indicate the agent(s) administered:etiolo
exer
he stu
he stu
uringcarring (nonreversible hypoperfusion or ventricular dys-
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December 30, 2008/January 6, 2009:91–124 Cardiac Imaging Data Standardsunction versus contrast-delineated necrosis/scar visualiza-
ion), myocardial abnormalities (normal versus scar versus
schemia versus mixed) and their severity are to be addressed
sing a standard 17-segment LV description (7). This
ermits a unified approach to study categorization, irrespec-
ive of the stress imaging modality. It is, however, recog-
ized that there can be significant patient-to-patient vari-
bility in the relationship between an LV myocardial
egment and the supplying coronary artery. It is also
nderstood that not all segments may be visualized for all
tudies or modalities given that certain techniques, such as
ingle-plane contrast ventriculography, would not allow for
t. The severity of the abnormality is to be graded as mild,
oderate, or severe; the definition of the severity isality Writing Committee. Subspecialty organizations,
owever, are encouraged to assign properties to each
ategory in the near future. The delineation of the size of
he abnormality is based on the number/location of the
nvolved segments. It is assumed that if a segment has an
bnormality, even if the complete segment is not com-
letely involved, it will be categorized as being abnormal.
geographically distinct second abnormality may also be
escribed.
When imaging of the coronary artery lumen is involved,
he assessment of diameter percent stenosis by coronary
istribution should be described according to a standard
-element description. For an example of a table for
isualization of the coronary territory, which includes theodality-dependent and beyond the scope of this multimo- 6-segment scheme, see Appendix C.
able 6. Study Findings—Ischemic Heart Disease
Element Name Definition
aseline ECG: Q-wave pathology
(Optional)
Indicate if pathologic Q waves were present on the baseline electrocardiogram (leads).
Choose 1 of the following:
● Yes
● No
● N/A
aseline ECG: Rhythm
(Recommended—CCTA, SPECT, CMR)
Indicate the patient’s baseline ECG rhythm.
Choose 1 of the following:
● Normal sinus rhythm
● Atrial fibrillation
● Premature atrial contractions
● Premature ventricular contractions
● Paced rhythm
● Atrial flutter
● Sinus tachycardia
● Sinus bradycardia
aseline ECG: ST-segment depression
(Optional)
Indicate if there was negative deflection below the isoelectric line greater than or
equal to 0.1 mV on the electrocardiogram (in mm).
Choose 1 of the following:
● Yes
● No
● N/A
aseline ECG readings
(Recommended—stress TTE, stress SPECT, stress PET,
CCTA, stress CMR)
Indicate whether any additional ECG findings were present.
Choose any of the following:
● Left bundle branch block
● Right bundle branch block
● Ventricular paced rhythm
● Pre-excitation
● Other
xercise capacity: METS
(Optional)
If exercise stress testing was performed during the study, indicate the number of
METS achieved (based on time completed for a specific protocol, using standardized
tables)
R response: Baseline heart rate
(Recommended—stress TTE, stress SPECT)
If stress testing was performed during the study, indicate the baseline heart rate.
R response: % Predicted heart rate response achieved
(Derived)
If stress testing was performed during the study, indicate the % predicted heart rate
response achieved.
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Element Name Definition
R response: Max heart rate
(Recommended—stress TTE, stress SPECT)
If stress testing was performed during the study, indicate the maximum heart rate.
R response: Heart rate recovery
(Optional)
If exercise stress testing was performed during the study, indicate the heart rate
recovery, defined as the reduction in the heart rate from the rate at peak exercise to
the rate 1 minute after the cessation of exercise.
Choose 1 of the following:
● Adequate (greater than 12 bpm)
● Inadequate (less than or equal to 12 bpm)
● Unknown
P response: Baseline systolic blood pressure
(Recommended—stress echo, stress SPECT)
If stress testing was performed during the study, indicate the first measurement or
earliest record of systolic blood pressure (in mm Hg) for this episode of care.
P response: Baseline diastolic blood pressure
(Recommended—stress echo, stress SPECT)
If stress testing was performed during the study, indicate the baseline diastolic blood
pressure (in mm Hg).
P response: Max systolic blood pressure
(Recommended—stress TTE, stress SPECT)
If stress testing was performed during the study, indicate the maximum systolic
pressure (in mm Hg).
P response: Max diastolic blood pressure
(Optional)
If stress testing was performed during the study, indicate the maximum diastolic
pressure (in mm Hg).
P and HR response: Double product
(Derived)
If stress testing was performed during the study, indicate the double product (heart
rate  systolic blood pressure).
tress testing: Chest pain during exercise
(Recommended—exercise SPECT, exercise TTE, stress PET)
If exercise stress testing was performed during the study, indicate the type of chest
pain.
Choose 1 of the following:
● Limiting chest pain
● Nonlimiting chest pain
● Anginal equivalent
● None
ufficient heart rate for exercise testing
(Derived)
If exercise stress testing was performed during the study, indicate whether the patient
is able to achieve 85% or greater of maximum predicted heart rate [(220  age in
years)  0.85].
Choose 1 of the following:
● Yes
● No
● N/A
CG: ST-segment depression
(Optional)
Indicate additional ST-segment depression beyond baseline. If baseline ST-segment
depression is greater than 1 mm, then uninterpretable.
Choose 1 of the following:
● None
● Less than 1 mm
● 1 mm
● 1.5 mm
● 3 mm
esults: Abnormality location, segments
(Recommended—stress SPECT, stress PET, stress TTE, stress CMR)
For each of the 17 myocardial segments, indicate whether it was normal, scarred,
ischemic, or mixed. If an abnormality was observed, indicate the severity as mild,
moderate, or severe.
An example of how this information could be collected, along with a diagram of the 17
segments, is included in Appendix D.
esults: Abnormality extent
(Derived)
Extent of abnormality based on number of segments within 17-segment model:
● None
● Small: 1 to 2 segments
● Moderate: 3 to 4 segments
● Large: greater than 5 segments
eport conclusions: ECG findings
(Recommended)
Indicate the conclusion derived from the ECG findings. Choose 1 of the following:
● Ischemia
● Equivocal
● Normal
● Nondiagnostic
● N/A
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he description of LV function was divided into systolic
nd diastolic components. The definition of diastolic dys-
unction was left broad in acknowledgment of differences in
apabilities of the various imaging modalities to investigate
he diastolic phase. Expansion of this category would be
esirable for certain modalities, especially echocardiography.
It was acknowledged that determination of systolic func-
ion, although pivotal to patient care, occurs with significant
ariability between the modalities. It is well appreciated that
ach imaging modality has a unique range of normal values
or quantitative ejection fraction determination. Even
ithin modalities, different quantitative methods may yield
isparate results, with differences in ejection fraction units,
t times, approaching 10 absolute units.
Although there was great discussion about the overall
oal and potential impact of describing LV systolic func-
able 6. Continued
Element Name
vidence of viability in the infarct zone
(Optional)
If
Ch
● S
● M
● L
● N
oronary calcium score
(Recommended—CACS)
If
oronary angiography (ICA and CCTA): Arterial segments
(Recommended—CCTA or ICA)
If
● L
● P
● M
● L
● R
● R
● S
● I
Fo
No
● L
● 5
● G
● O
An
oronary angiography (invasive and CCTA): Dominance
(Recommended—CCTA or ICA)
In
● L
● R
● C
oronary angiography (ICA and CCTA): Coronary anomalies
(Optional)
If
● Y
● N
/A indicates not applicable.ion, the majority of the panel felt that uniformity should be tttempted, and the final consensus was that, as a required
ata element, this section incorporates only 4 categories
or systolic function: normal, mildly reduced, moderately
educed, and severely reduced. It was also agreed that a
ange of quantitative values should be elucidated for
iffering degrees of LV dysfunction. For purposes of
eporting a specific value, the mid point of the range may
e used, such that moderate LV dysfunction would be
eported as 35%.
The quantitative value for ejection fraction was recom-
ended to be reported as an optional item. The measured
uantitative ejection fraction could be reported as a specific
alue (e.g., 64%) or a 5% range (e.g., 30% to 35%). The mid
oint of the range would be used for data collection/storage.
t was noted that, overall, the precision on this measure is
oor, as is its reproducibility for some modalities; however,
he error range for this measurement is implicit. Although
Definition
ion defects or wall motion abnormalities are present, indicate the degree of
ity.
1 of the following:
ate
ary CT calcium score is performed, provide Agatston score.
ary angiography was performed, indicate the arterial segments visualized.
e any of the following:
ain
al LAD and 1st diagonal branches
istal LAD, D2 and D3 branches
Ms, LPDA and LPL branches
PDA, RPL, AM branches
neous vein grafts or free arterial grafts, if relevant
l mammary artery (LIMA, RIMA), if relevant
segment visualized, indicate the percent stenosis:
an 50%
70%
r than 70%
ed
ple of how this information could be collected is included in Appendix C.
the anatomic coronary dominance (which coronary provides the posterior
nding artery and PL branches).
inant
ary angiography was performed, indicate whether coronary anomalies, such as
mal origin or location, are present.perfus
viabil
oose
mall
oder
arge
one
coron
coron
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ead to variability. Differing methodological approaches
e.g., count-based, 3-dimensional count-based) further in-
rease variability. When reported as a numerical value, the
maging modality and method of analysis (visual, quantita-
ive) should be specified.
The Writing Committee felt that a standard for LV
unction must be established, although cognizant of the
ontroversies and challenges. One option for future research
ay be the use of a regression analysis, whereby a given
jection fraction obtained using a specific method could
e converted into a “universal ejection fraction,” thereby
liminating modality-specific differences in ranges ofalculations of volumetric data from geometric assumptions
f
t
t
s
f
D
/A indicates not applicable.f LV function was felt to be the most useful parameter,
ith modality-specific definitions contained within each
ategory.
To attain consistency between methods, regional systolic
unction is defined using the 17-segment scheme. Broad
ategories of hypokinesis, akinesis, and dyskinesis are rec-
mmended to describe regional dysfunction (16). The panel
ecognized that differentiation among these wall motion
ategories may be difficult and subjective, and that the
linical relevance between akinesis and dyskinesis may not
e high. However, it was agreed that additional layers of
ranularity for hypokinetic regions was likely not useful. For
eporting purposes, if global hypokinesis is present, scoringysfunction. However, at the current time, the category for each segment should be performed.
able 7. Study Findings—LV Function
Element Name Definition
V diastolic function
(Recommended)
Indicate the overall assessment of LV diastolic function.
Choose 1 of the following:
● Normal for age
● Abnormal for age
● N/A
esting LV systolic function: Global wall motion abnormalities:
Ejection fraction (EF)/LVEF
(Optional)
Indicate the calculated ejection fraction (actual value or midpoint of range).
Or not applicable.
ethod of LVEF calculation
(Optional)
Indicate the method of LVEF calculation. Choose 1 of the following:
● Visual
● Quantitative
esting LV systolic function: Global function: Ejection fraction
(EF) (Recommended)
Indicate the ejection fraction category. Choose 1 of the following:
● Hyperdynamic: greater than 70%
● Normal: 50% to 70% (midpoint 60%)
● Mild dysfunction: 40% to 49% (midpoint 45%)
● Moderate dysfunction: 30% to 39% (midpoint 35%)
● Severe dysfunction: less than 30%
V wall motion abnormalities—17 segment
(Recommended—SPECT, echo, CMR) (Optional—CCTA)
Assess regional function in each of the 17 myocardial segments by
indicating if it was normal, hypokinetic, akinetic, dyskinetic, or not
visualized.
An example of how this information could be collected, along with a
diagram of the 17 segments, is included in Appendix E.
V wall motion abnormalities—10 segment
(Optional—LVG)
Assess regional function in each of the 10 myocardial segments by
indication if it was normal, hypokinetic, akinetic, dyskinetic or not
visualized.
An example of how this information could be collected, along with a
diagram of the 10 segments, is included in Appendix F.. Study Findings—Cardiac Morphology
n the reporting of cardiac morphology, presentation of
-dimensional volumetric data in regards to LV end-
iastolic and -systolic volumes, LV mass, and ejection
raction is optimal. In the absence of 3-dimensional data,rom 2-dimensional data sets can be substituted. Alterna-
ively, 2-dimensional measures of chamber sizes and wall
hicknesses could be reported.
Assessment of severity of valvular regurgitation and
tenosis should follow current ACC/AHA 2006 Guidelines
or the Management of Patients With Valvular Heart
isease (17).
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Element Name Definition
hamber volume: Left ventricle
(Recommended)
Choose 1 of the following:
● Normal
● Enlarged
● Small
● Not reported
hamber volume: Left ventricle, systolic
(Optional)
Described in ml or not reported.
hamber volume: Left ventricle,
diastolic
(Optional)
Described in ml or not reported.
hamber size: Right ventricle
(Recommended—TTE, TEE, CMR)
(Optional—CCT)
Choose 1 of the following:
● Normal
● Enlarged
● Not reported
hamber size: Left atrium
(Recommended—TTE, TEE, CMR)
(Optional—CCT)
Choose 1 of the following:
● Normal
● Enlarged
● Not reported
hamber size: Right atrium
(Recommended—TTE, TEE, CMR)
(Optional—CCT)
Choose 1 of the following:
● Normal
● Enlarged
● Not reported
all thickness: Left ventricle: Septum:
end-diastolic thickness
(Optional)
Indicate the end-diastolic thickness of the mid-septum, in mm.
all thickness: Left ventricle:
Inferolateral wall: end-diastolic
thickness
(Optional)
Indicate the end-diastolic thickness of the mid-inferolateral wall, in mm.
all thickness: Right ventricle:
Free wall: end-diastolic thickness
(Optional)
Indicate the end-diastolic thickness of the mid-free wall.
Choose 1 of the following:
● Normal
● Increased
● Not reported
eft ventricular myocardial mass
(Optional)
Indicate assessment of left ventricular myocardial mass.
Choose 1 of the following:
● Normal
● Increased
● Not reported
eft ventricular myocardial mass:
By body surface area
(Derived)
Indicate the left ventricular myocardial mass indexed by body surface area.
Choose 1 of the following:
● Normal
● Increased
● Not reported
ulmonary veins
(Optional—CMR, CCT)
Assessment of pulmonary venous configuration in preparation for pulmonary vein isolation/radiofrequency
ablation of atrial fibrillation.
Choose 1 of the following:
● Normal (4 pulmonary veins, normal pulmonary venous drainage into left atrium)
● Variant (variant number of pulmonary veins (usually 3 or 5), but with normal pulmonary venous drainage
into left atrium)
● Anomalous (anomalous drainage of 1 or more pulmonary veins into a chamber other than the left atrium)
ntracardiac (nonvalvular) mass: Type
(Optional)
If an intracardiac mass is present, indicate the type of intracardiac mass.
Choose 1 of the following:
● None
● Vegetation
● Thrombus
● Neoplasm
● Unknown
TI
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Element Name Definition
ntracardiac shunt
(Optional)
Indicate if the patient has evidence for an intracardiac shunt and etiology.
Choose 1 of the following:
● None
● PFO
● ASD
● VSD
● PDA
● Other
ericardial: Effusion
(Recommended—TTE, TEE, CCT, CMR)
Indicate if pericardial effusion is present.
Choose 1 of the following:
● Present
● Absent
ericardial: Effusion: Size
(Optional)
If pericardial effusion is present, indicate the overall assessment of its size and/or the maximal end-
systolic dimension of the pericardial effusion.
Choose 1 or more of the following:
● Trivial
● Small
● Moderate
● Large
ericardial effusion: Evidence of increased
intrapericardial pressure
(Optional)
If pericardial effusion is present, indicate if tamponade is present.
Choose 1 of the following:
● Present
● Absent
● Equivocal
● Not assessed
ericardial: Thickness
(Optional)
Indicate the thickness of the pericardium.
Choose 1 or more of the following:
● Normal
● Thickened
● Calcified
● Not assessed
alvular: Aortic: Structure
(Recommended—TTE, TEE, CCT, CMR)
Indicate if the structure of the aortic valve is abnormal.
Choose 1 of the following:
● Normal
● Abnormal
● Prosthetic
● Not assessed
alvular: Aortic: Structure: Cause of abnormality
(Optional)
If the aortic valve is abnormal, indicate the cause of abnormality in the aortic valve.
Choose any of the following:
● Congenital leaflet abnormality
● Leaflet thickening/calcification
● Vegetation/mass
● Other
● None
● N/A
alvular: Aortic: Stenosis
(Recommended—TTE, TEE, CMR, cardiac cath)
Indicate the severity of stenosis in the aortic valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
TV
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Element Name Definition
alvular: Aortic: Regurgitation
(Recommended—TTE, TEE, CMR, cardiac cath)
Indicate the severity of regurgitation in the aortic valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
alvular: Mitral: Structure
(Recommended—TTE, TEE, CMR)
Indicate if the structure of the mitral valve is abnormal.
Choose 1 of the following:
● Normal
● Abnormal
● Prosthetic
● Annuloplasty ring
● Not assessed
alvular: Mitral: Structure: Abnormal
(Recommended—TTE, TEE, CMR)
If the mitral valve is abnormal, indicate the location of the abnormality of the mitral valve.
Choose 1 or more of the following:
● Congenital leaflet abnormality
● Leaflet thickening/calcification
● Vegetation/mass
● Flail
● Prolapse
● None
● Not assessed
alvular: Mitral: Annular calcification
(Recommended—TTE, TEE, CCT, CMR,
cardiac cath)
Indicate if there is annular calcification in the mitral valve.
Choose 1 of the following:
● Present
● Absent
● Not assessed
alvular: Mitral: Stenosis
(Recommended—TTE, TEE, CMR, cardiac cath)
Indicate the severity of stenosis in the mitral valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
alvular: Mitral: Regurgitation
(Recommended—TTE, TEE, CMR, cardiac cath)
Indicate the severity of regurgitation in the mitral valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
alvular: Tricuspid: Structure
(Recommended—TTE, TEE, CMR)
Indicate if the structure of the tricuspid valve is abnormal.
Choose 1 of the following:
● Normal
● Abnormal
● Prosthetic
● Annuloplasty ring
● None
● Not assessed
TV
V
V
V
V
A
A
A
N
116 Hendel et al. JACC Vol. 53, No. 1, 2009
Cardiac Imaging Data Standards December 30, 2008/January 6, 2009:91–124able 8. Continued
Element Name Definition
alvular: Tricuspid: Stenosis
(Recommended—TTE, TEE, CMR)
Indicate the severity of stenosis in the tricuspid valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
alvular: Tricuspid: Regurgitation
(Recommended—TTE, TEE, CMR)
Indicate the severity of regurgitation in the tricuspid valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
alvular: Pulmonic: Structure
(Recommended—TTE, TEE, CMR)
Indicate if the structure of the pulmonic valve is abnormal.
Choose 1 of the following:
● Normal
● Abnormal
● Prosthetic
● None
● Not assessed
alvular: Pulmonic: Stenosis
(Recommended—TTE, TEE, CMR)
Indicate the severity of stenosis in the pulmonic valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
alvular: Pulmonic: Regurgitation
(Optional)
Indicate the severity of regurgitation in the pulmonic valve.
Choose 1 of the following:
● Mild
● Moderate
● Severe
● None
● Not assessed
orta: Dissection
(Recommended—TTE, TEE, CMR, CCTA, cardiac
cath)
Indicate if the aorta is dissected.
Choose 1 of the following:
● Present
● Absent
● Not assessed
orta: Dissection: Present: Stanford Classification
(Recommended—TTE, TEE, CMR, CCTA, cardiac
cath)
If the aorta is dissected, indicate the type of dissection that is present in the aorta.
Choose 1 of the following:
● Stanford type A—all dissections involving the ascending aorta regardless of site of origin
● Stanford type B—all dissections not involving the ascending aorta
ortic Root: Dilation: Enlarged Indicate if the aortic root is dilated.
Choose 1 of the following:
● Present
● Absent
● Not assessed/A indicates not applicable.
II
fi
s
S
A
J
C
T
s
D
a
M
S
D
E
P
A
M
R
e
G
P
R
1
1
1
1
T
R
R
R
D
S
R
N
117JACC Vol. 53, No. 1, 2009 Hendel et al.
December 30, 2008/January 6, 2009:91–124 Cardiac Imaging Data Standards. Study Findings—Summary
n order to provide an overall conclusion regarding study
ndings, Table 9 was developed to report an overall impres-
ion of results related to Tables 6, 7, and 8.
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awn R. Phoubandith, MSW, Associate Director, Science
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able 9. Study Findings—Summary
Element Name Definition
eport conclusions: Overall
summary
(Recommended—ICA)
Indicate conclusions derived from ischemic
heart disease assessment. Choose 1 of
the following:
● Normal
● Abnormal
● Equivocal
● N/A
eport conclusions: Ischemia
(Recommended—CCTA,
ICA, stress SPECT,
stress echo)
Indicate whether there is evidence for
ischemia on the study. Choose 1 of the
following:
● Yes
● No
● Equivocal
● N/A
eport conclusions:
Ventricular function
(Recommended)
Indicate the conclusion derived from the
ventricular function assessment. Choose
1 of the following:
● Normal
● Equivocal
● Abnormal
● N/A
ate of Prior Study
(Recommended)
Indicate the date of prior imaging study
done.
ignificant changes from
prior study
(Recommended)
Indicate if there are significant changes
from prior study. Choose 1 of the
following:
● Yes
—Describe changes from prior study
● No
● N/A
eport finalized with
signature date
(Recommended)
Indicate the date the report was finalized
and signed by the interpreting physician.
/A indicates not applicable.an Roman, Specialist, Healthcare Technologyrin A. Barrett, Senior Specialist, Science and Clinical
olicy
merican Heart Association
. Cass Wheeler, Chief Executive Officer
ose Marie Robertson, MD, FACC, FAHA, Chief Sci-
nce Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
resident, Office of Science Operations
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Coronary Territory Not Visualized
Percent Stenosis
Less Than 50% 50% to 70% Greater Than 70% Occluded (100%)
1. Left main
2. Proximal LAD and 1st diagonal branches
3. Mid/distal LAD, D2, and D3 branches
4. LCX, OMs, LPDA, and LPL branches
5. RCA, RPDA, RPL, and AM branches
6. Ramus
7. LIMA, if applicable
8. RIMA, if applicable
9. SVG to —, if applicable
AF
A
122 Hendel et al. JACC Vol. 53, No. 1, 2009
Cardiac Imaging Data Standards December 30, 2008/January 6, 2009:91–124PPENDIX D. TABLE FOR ASSESSMENT OF ISCHEMIA AND SCAR BASED ON 17 MYOCARDIAL SEGMENTS
Myocardial Segment Not Visualized
Type of Abnormality Severity, If Abnormal
Normal Scar Ischemia Mixed Mild Moderate Severe
1. Basal anterior
2. Basal anteroseptal
3. Basal inferoseptal
4. Basal inferior
5. Basal inferolateral
6. Basal anterolateral
7. Mid anterior
8. Mid anteroseptal
9. Mid inferoseptal
10. Mid inferior
11. Mid inferolateral
12. Mid anterolateral
13. Apical anterior
14. Apical septal
15. Apical inferior
16. Apical lateral
17. Apex
igure D1. Left Ventricular Segmentation
dapted from Cerqueira MD et al. (8).
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Myocardial Segment
Regional Function
Normal Hypokinetic Akinetic Dyskinetic Not Visualized
1. Basal anterior
2. Basal anteroseptal
3. Basal inferoseptal
4. Basal inferior
5. Basal inferolateral
6. Basal anterolateral
7. Mid anterior
8. Mid anteroseptal
9. Mid inferoseptal
10. Mid inferior
11. Mid inferolateral
12. Mid anterolateral
13. Apical anterior
14. Apical septal
15. Apical inferior
16. Apical lateral
17. Apex
igure E1. Left Ventricular Segmentationdapted from Cerqueira MD et al. (8).
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CONTRAST LEFT VENTRICULAR ANGIOGRAPHY)
Myocardial
Segment
Regional Function
Normal Hypokinetic Akinetic Dyskinetic Not Visualized
1. Anterobasal
2. Anterolateral
3. Apical
4. Diaphragmatic
5. Posterobasal
6. Basal septal
7. Apical septal
8. Posterolateral
9. Inferior lateral
10. Superior lateral
igure F1. Diagrammatic Representation of RAO and LAO Views of the LV Obtained During Contrast Angiography Showing Division of
he LV Wall Into 10 Numbered Segments
dapted from Wexler LA et al. (16). LA indicates left atrium; LAO  left anterior oblique; RAO  right anterior oblique.
